Molecule to Medicine

Managing the transition from discovery to development

Date: 17 May - 20 May 2021

Location: Online Event

Tutors: Dr John Studley

We are delighted to be offering this course now ON LINE, the two day course has now been divided up into four sessions, which will be delivered via an on line platform.  Dates and timings are as follows and are set in GMT time (Greenwich Mean Time).

Monday May 17th | 2.00pm – 5.00pm BST
Tuesday May 18th | 2.00pm – 5.00pm BST
Wednesday May 19th 
| 2.00pm – 5.00pm BST
Thursday May 20th | 2.00pm – 5.00pm BST

The aim of this course is to provide attendees with a good basis to work from when involved in taking development candidates to the first in human trials with a view also on some longer-term requirements.  The course content will therefore focus on the necessary early phases of chemical development as  would typically be required to support production of up to about 2kg using laboratory-based 20L equipment and pilot plant equipment. The course will  introduce and discuss the following:

Requirements in order to move from small (<1g) supplies to the first 100g or so for preclinical work
> Further scaling to 1-2kgs non-cGMP
> Requirements to make material for use in clinical trial – an introduction to cGMP coupled with the scaling issues
> An overview of the requirements to move processes to fixed vessels, assuming cGMP is required – what operations can readily be transferred and those that should ideally be developed out
> The importance of physical form selection, understanding and control
> Impurities and their control, with specific discussion on genotoxic impurities and developing the specification for the API as it moves from preclinical  batch preparation to cGMP batches for clinical trials.

For more information please do download the brochure (this is based on the live course, but the content is the same)

Book Now

Remind Me

Download Brochure Booking Form

Remind me about this course

We'll remind you a month before this course starts or if we're running out of spaces. Enter your email address below.

Course Outline

Session 1:
Introduction to typical pharmaceutical development activities and timeframes for toxicological studies. Explore the interface between discovery chemistry and development- what can we learn from each other? Key interactions between medicinal chemists and process chemists. Discuss how rapidly we can we move a molecule into phase 1, the planning required to expedite the process and staying on top of compound supply.  Communication, working with other
disciplines and managing expectations.  How to plan for the unexpected. Contingency planning and redundancy in material supply.

Session 2:
Making the first 100g non-GMP batch for GLP toxicological studies; discussion of topics such as setting the specification, the use of chromatography,  accessing starting materials, identifying how much development to do.

Session 3:
Non-GMP vs GMP preparation. A brief introduction to GMPs and how they impact on the initial chemistry scaling exercise.

Session 4:
Physical version and form, spending time on the importance of salt selection, especially in the early phases of development with form/polymorph considerations also being discussed. There will be a brief introduction of polymorphism and which aspects of physical form should ideally be established at the early phase of development.

Session 5:
Process safety and raw materials supply issues and how these might impact on the chosen route.

Session 6:
Review of the day and questions.

Session 7:
Scaling into fixed vessels with discussions about those operations that transfer well and those which typically do not.

Session 8:
Technology transfer and a discussion of the issues and suggestions to mitigate against them.

Session 9:
A presentation about genotxoic impurities – what are they, what are the suggested control levels, how well do chemists identify them?

Session 10:
A presentation about impurities, including their identification, isolation/ preparation and control with discussions about setting specifications.

Session 11:
The final session of the course will review the two days and follow-up on any questions.

Case Studies and Problem sessions will also be included and audience participation is encouraged throughout the course.


Key Learning Opportunities

  • How long does it take to get from milligrams to 1-2kgs suitable for human clinical trials?
  • What are the main hurdles?
  • What can be left out and what must be included?
  • What are the key and strategic Project managers and those
    involved in technical outsourcing

Who Should Attend

  • Project managers and those involved in technical outsourcing
  • Project leaders and bench chemists involved in preparation of material
  • New starters to the area
  • Medicinal Chemistry support teams involved in making the first batches for toxicological evaluation

What's Included

The course fee includes:

  • Link to watch all four live sessions
  • Electronic version of the course manual*
  • Course certificate

For this on line course, there will be no recordings available and *the e reader manual is NOT printable or downloadable (due to copyright).  If you prefer a hard copy of the manual you will have the opportunity of purchasing a professionally printed hard copy during the booking process.


I am not a chemist, however, the course was very informative and it allowed me to see the big picture from discovery stage to pilot plant.

Genentech Delegate